A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

This study is looking for women with a specific type of ovarian cancer (high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer) that has come back. You would need to have clear signs of the cancer on scans or tests.

Whether you can join also depends on your previous treatments. For example, some parts of the study are for those whose cancer returned more than 6 months after their last platinum-based chemotherapy (meaning your cancer is 'platinum-sensitive'), while other parts are for those whose cancer came back sooner than 6 months (meaning your cancer is 'platinum-resistant'). There are also specific rules about how many previous treatments you've had, especially if you've had bevacizumab or a type of drug called PARPi.

To be considered, you'll need to be generally well enough to take part and have a tissue sample from your cancer available. If you have conditions like HIV or hepatitis, you might still be able to join if these conditions are well controlled with treatment.

The detailed participation requirements would be explained by the study team, but generally, this type of study involves regular hospital visits for assessments, including blood tests, scans (like CT scans), and physical examinations. You would be given the study drug, Raludotatug deruxtecan, and potentially other standard treatments, either through an injection or as tablets, according to a set schedule. There would also be follow-up appointments to monitor your health and how you respond to the treatment. The total duration of your involvement would depend on how your cancer responds to the treatment and the specific part of the study you are in.